Despite new medication, cystic fibrosis often leads to permanent lung damage. Working with an international team, researchers from the Technical University of Munich (TUM) have discovered that the ...

Vertex Pharmaceuticals (NASDAQ:VRTX), a leading biotechnology company known for its cystic fibrosis (CF) treatments, is at a critical juncture as it seeks to diversify its portfolio and maintain its ...

CRISPR & Cas Genes Market Growing funding in gene therapy worldwide is a prominent factor driving the CRISPR & Cas genes market.

Some you might hold only temporarily, while others you own for decades. David Jagielski (Eli Lilly): A forever stock you can ...

Vertex Pharmaceuticals (VRTX) stock has performed strongly since the turn of the year, gaining 14.6% and vastly outperforming the healthcare ...

Vertex Pharmaceuticals (NASDAQ:VRTX), a leading biotechnology company with a market capitalization of $113.7 billion, is navigating a critical juncture as it seeks to expand its therapeutic reach and ...

Discover the importance of vision, genetic eye disorders, and RNA-based therapies for precision treatment in India and ...

In this installment of Rebelliously Curious, we delve into one of the most debated scientific advancements of our time: CRISPR gene-editing technology. Joining us is Neal Baer, M.D.—pediatrician, ...

Currently, many gene therapies using viral-free vectors rely on ex vivo editing. This involves removing a patient’s cells, editing them in a lab, and reintroducing them into the body. While effective, ...

Today, a brief rundown of news involving Intellia Therapeutics and ArriVent BioPharma, as well as updates from Atara Biotherapeutics, Amylyx Pharmaceuticals and InnoCare Pharma that you may have ...

CapCut, a popular video-editing app, came back online in the United States on Tuesday after going dark over the weekend. Users who opened the app or visited its website were greeted with a pop-up ...

Metagenomi is now working on preclinical studies to advance MGX-001, its experimental gene-editing therapy for hemophilia A, with the goal of bringing the treatment candidate into clinical trials in ...